Endogenous estrogen levels and Alzheimer's disease among postmenopausal women

Neurology

Volumn 54, Issue 4, 2000, Pages 833-837

  Manly, J J ^a   Merchant, C A ^a   Jacobs, D M ^a   Small, S A ^a   Bell, K ^a   Ferin, M ^b   Mayeux, Richard ^a  

^a Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^b Gertrude H Sergievsky Center ^*  (United States)

Author keywords

AD; Estradiol levels; Estrone levels; Hormone replacement therapy

Indexed keywords

ESTROGEN;

AGED; ALZHEIMER DISEASE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE ASSOCIATION; ESTRONE BLOOD LEVEL; FEMALE; HORMONE SUBSTITUTION; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0034700965     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.54.4.833     Document Type: Article

References (41)

1. Kimura D, Estrogen replacement therapy may protect against intellectual decline in postmenopausal women. Horm Behav 1995;29:312-321.
2. Robinson D, Friedman L, Marcus R, Tinklenberg J, Yesavage J. Estrogen replacement therapy and memory in older women. J Am Geriatr Soc 1994;42:919-922.
3. Jacobs DM, Tang M-X, Stern Y, et al. Cognitive function in nondemented older women who took estrogen after menopause. Neurology 1998;50:368-373.
4. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994;140: 256-261.
5. Tang M-X, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease [see comments]. Lancet 1996;348:429-432.
6. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging. Neurology 1997;48:1517-1521.
7. Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaoi Y, Hagino N. Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type: 7 case reports. Dementia 1995;6:99-107.
8. Fillit H, Weinreb H, Cholst I, et al. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology 1986;11:337-345.
9. Honjo H, Ogino Y, Naitoh K, et al. In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type). J Steroid Biochem 1989;34:521-525.
10. Yaffe K, Grady D, Pressman A, Cummings S. Serum estrogen levels, cognitive performance, and risk of cognitive decline in older community women. J Am Geriatr Soc 1998;46:816-821.
11. Kampen DL, Sherwin BB. Estrogen use and verbal memory in healthy postmenopausal women. Obstet Gynecol 1994;83: 979-983.
12. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of senile change in the cerebral grey matter of elderly subjects. Br J Psychol 1968;114:797-811.
13. Boller F, Mizutani T, Roessmann U, Gambetti P. Parkinson's disease, dementia, and Alzheimer disease, clinicopathological correlations. Ann Neurol 1980;7:329-335.
14. Katzman R, Brown T, Fuld P. Validation of a short orientation-memory-concentration test of cognitive impairment. Am J Psychiatry 1983;140:734-738.
15. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, revised third edition. Washington, DC: American Psychiatric Press, 1987.
16. Stern Y, Andrews H, Pittman J, et al. Diagnosis of dementia in a heterogeneous population. Development of a neuropsychological paradigm-based diagnosis of dementia and quantified correction for the effects of education. Arch Neurol 1992; 49:453-460.
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
18. Schwab JF, England AC, Gillingham FH, Donaldson MC. Projection technique for evaluating surgery in Parkinson's disease. In: Third symposium on Parkinson's disease. New York, NY: Churchill Livingstone, 1969:152-157.
19. Burke WJ, Miller JP, Rubin EH. The reliability of the Washington University Clinical Dementia Rating. Arch Neurol 1988;45:31-32.
20. Hixson J, Vernier D. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhAI. J Lipid Res 1991;31:545-548.
21. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women. JAMA 1998;279:688-695.
22. Singh M, Meyer EM, Simpkins JW. The effect of ovariectomy and estradiol replacement on brain-derived neurotrophic factor messenger ribonucleic acid expression in cortical and hippocampal brain regions of female Sprague-Dawley rats. Endocrinology 1995;136:2320-2324.
23. Jaffe AB, Toran-Allerand CD, Greengard P, Gandy SE. Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein. J Biol Chem 1994;269:13065-13068.
24. Gridley KE, Green PS, Simpkins JW. A novel, synergistic interaction between 17 beta-estradiol and glutathione in the protection of neurons against beta-amyloid 25-35-induced toxicity in vitro. Mol Pharmacol 1998;54:874-880.
25. Gridley KE, Green PS, Simpkins JW. Low concentrations of estradiol reduce beta-amyloid (25-35)-induced toxicity, lipid peroxidation and glucose utilization in human SK-N-SH neuroblastoma cells. Brain Res 1997;778:158-165.
26. Xu H, Gouras GK, Greenfield JP, et al. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nature Med 1998;4:447-451.
27. Toran-Allerand CD, Miranda RC, Bentham WD, et al. Estrogen receptors colocalize with low affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci USA 1992;89:4668-4672.
28. McEwen BS, Wooley CS. Estradiol and progesterone regulate neuronal structure and synaptic connectivity in adult as well as developing brain. Exp Gerontol 1994;29:431-436.
29. Applebaum-Bowden D, McLean P, Steinmetz A, et al. Lipoprotein, apolipoprotein, and lipolytic enzyme changes following estrogen administration in postmenopausal women. J Lipid Res 1989;30:1895-1906.
30. Longscope C. Methods and results of aromatization studies in vivo. Cancer Res 1982;42:3307s-3311s.
31. van Beresteign EC, van Laarhoven JP, Smals AG. Body weight and/or endogenous estradiol as determinants of cortical bone mass and bone loss in healthy early postmenopausal women. Acta Endocrinologia 1992;127:226-230.
32. Meldrum DR, Davison BJ, Tataryn IV, Judd HL. Changes in circulating steroids with aging in postmenopausal women. Obstet Gynecol 1981;57:624-628.
33. Longscope C, Baker S. Androgen and estrogen dynamics: relationships with age, weight, and menopausal status. J Clin Endocrinol Metab 1993;73:601-604.
34. Franklin CA, Karkeck J. Weight loss and senile dementia in an institutionalized elderly population. J Am Diet Assoc 1989; 89:790-792.
35. Sandman O, Adolsson R, Nygren C. Nutritional status and dietary intake in institutionalized patients with Alzheimer's disease and multiinfarct dementia. J Am Geriatr Soc 1987;35: 31-38.
36. Singh S, Mulley GP, Losowsky MS. Why are Alzheimer's patients thin? Age Ageing 1988;17:21-28.
37. Du W, DiLuca C, Growdon JH. Weight loss in Alzheimer's disease. J Geriatr Psychiatr Neurol 1993;1:34-38.
38. Berlinger WG, Potter JF. Low body mass index in demented outpatients. J Am Geriatr Soc 1991;39:973-978.
39. Tham D, Gardner CD, Haskell WL. Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab 1998;83:2223-2235.
40. Baird DD, Umbach DM, Lansdell L, et al. Dietary intervention study to assess estrogenicity of dietary soy among postmenopausal women. J Clin Endocrinol Metab 1995;80: 1685-1690.
41. Molnar G, Kassai-Bazsa Z. Gonadotropin, ACTH, prolactin, sexual steroid and cortisol levels in postmenopausal women's cerebrospinal fluid (CSF). Arch Gerontology Geriatrics 1997; 24:269-280.